(FORT WORTH, TX) —HEALTHPOINT, Ltd. today announced that it has enrolled the first of a planned 235 subjects into a Phase II dose response study investigating an experimental, cell-based wound therapy ---HP802-247---intended for the treatment of venous leg ulcers. HP802-247 is a topical spray containing living keratinocytes and fibroblasts. The first patient was enrolled at The Center for Clinical Research near San Francisco, Calif., led by the site’s principal investigator, Alexander Reyzelman, DPM. The study is being conducted by 28 investigators in 18 states.
Tue, 06/16/2009
|
||
|
Tue, 11/25/2008
(Fort Worth, TX) --- H. Paul Dorman, Chairman and Chief Executive Officer of Fort Worth-based DFB Pharmaceuticals, Inc., has announced that Travis E. Baugh has joined HEALTHPOINT®, Ltd., a DFB Pharmaceuticals company, as President and Chief Operating Officer. |
||
Mon, 09/08/2008
HEALTHPOINT, Ltd., a DFB Pharmaceuticals, Inc. affiliate company and Hydrofera, LLC, announced the signing of a distribution agreement for Hydrofera Blue® Brand wound care products. As part of the agreement, HEALTHPOINT has immediate responsibility for marketing, selling, and distribution of Hydrofera Blue® Brand. Terms of the deal were not disclosed. |
||
Tue, 08/26/2008
FORT WORTH, TX, AUGUST 26, 2008 – Healthpoint today announced that it has initiated a clinical trial to evaluate the effectiveness of a widely prescribed enzymatic debriding agent on healing cutaneous wounds and resulting scars. The pilot study was prompted, in part, by clinical reports of the reduced incidence of hypertrophic scars and beneficial healing properties associated with Collagenase SANTYL® Ointment.1,2 |
||
|
Mon, 06/30/2008
FORT WORTH, TX, JUNE 30, 2008 – The Wound Institute (TWI) today announced the launch of a new educational module “Chronic Wound Infections®”, a CE accredited, online course designed to strengthen clinicians’ diagnostic skills and enhance treatment for improved clinical outcomes. |
